Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Stock data | 2024 | Change |
---|---|---|
Price | $1.09 | N/A |
Market Cap | $14.64M | N/A |
Shares Outstanding | 13.44M | N/A |
Employees | 14.00 | N/A |